TherapeuticsMD, Inc.TXMD

The first-quarter 2026 filing from TherapeuticsMD, Inc. shows the company collected $724,000 of licence revenue-mostly from the Mayne licence agreement-while burning $723,000 in operating losses and netting a $95,000 loss for the quarter, all on a balance sheet that still carries $5.7 million of cash left over from 2025. The diluted earnings per share clocked in at one cent, and the weighted average diluted share count was a Lilliputian 11,640 units, fewer than the staff of a single London branch of Boots the Chemist.

TherapeuticsMD is a women’s health company whose public pages trumpet IMVEXXY® and BIJUVA®, two branded prescription assets whose names read like a marketing team’s Scrabble high-score attempt after one too many espressos. In reality, the company acts primarily as a licensor of assets it acquired from third parties, not a manufacturer of its marquee products. The patents page claims domestic and international protections for those same products, but patents alone do not fill the cash register when aggregate U.S. product sales-if disclosed-remain below the radar of a quiet GP’s waiting room.

The 10-Q for the quarter ending 31 March 2026 lists total assets of $37.6 million against liabilities of $10.6 million, giving shareholders’ equity of $27.0 million. Management still dangled milestone payments in the filings-$5 million if annual U.S. sales reach $100 million, $10 million at $200 million, and $15 million at $300 million-yet the same filing does not disclose actual product sales for the quarter, leaving investors to guess whether the milestones are a carrot or a hologram. The company also disclosed service agreements with MCD Consulting and JZ Advisory Group in the 10-K/A, which are less growth engines than invoices-in-waiting.

For a company whose market story hinges on milestone payments that remain hypothetical, the most concrete number in the latest package is the $5.7 million cash balance-carried at the 31 March 2025 value-implying the company has spent down its cash in the year since. TherapeuticsMD’s equity base is thin enough that any dilution would be felt in proportion, not in noise; at 11,640 diluted shares, a 10% equity raise would add fewer than 1,200 shares, a rounding error in most market contexts but a material slice for this micro-cap. The filings do not provide segment-level revenue, capex, R&D spend, or guidance, so the file’s operating reality remains opaque beyond the headline licence revenue and the persistent operating loss.

The company’s filing index on SEC EDGAR lists the usual parade of 10-Q, 10-K/A, 8-K and NT 10-K documents, yet none of them disclose the quarterly product sales figures that would let outsiders judge whether the milestone carrot is getting closer or merely receding. The only cited source for product descriptions and patents is TherapeuticsMD’s own web rails, which are marketing materials, not audited financial statements. Until the company starts filing sales-by-product or at least by segment, the file remains a set of promises wrapped in red tape rather than a business story grounded in numbers.

TherapeuticsMD’s SEC submissions JSON and companyfacts JSON are both available on the SEC site, but neither endpoint supplies sales or cash-flow data beyond what is already captured in the 10-Q; they are metadata rails, not primary financials. The company’s Schedule 13G filing from April 2026 shows a passive institutional holder, but the document carries no insight into operating momentum. In short, the file is rich in process and poor in proof: filings, service agreements, and brand pages abound, while audited sales, R&D spend, and segment performance remain unseen.